From Glycemic Control to Cardiorenal Protection: Improving Outcomes With SGLT2 Inhibitors

May 15, 2021

Experts Dr. Lawrence Leiter (Chair), Dr. Jennifer Green, Dr. Javed Butler, and Dr. David Cherney from multiple specialties (endocrinology, cardiology, and nephrology) will through lecture, case presentations, and panel discussion, provide perspectives on translating evidence into clinical practice and indicate considerations for using SGLT2 inhibitors safely and effectively in patients with, and at high risk for CV disease, HF, and chronic kidney disease (CKD).

2.00 Credits

New Pathways to GLYCEMIC CONTROL: Focus on the Kidney

October 28, 2014

Presentations by Jay Shubrook, DO (Chair), Eugene Cersosimo, MD, PhD, and Robert Henry, MD. discussing the role of glucose regulation and SGLT 2 inhibitors in antihyperglycemic therapy

No Credit Available